Anti-Hypertensive Drugs Market Size to Grow at a CAGR of 4.1% During the Forecast Period 2020–2025

Anti-Hypertensive Drugs Market Overview Anti-Hypertensive Drugs Market size is valued at $24.2Bn by 2019, and is anticipated to grow at a CAGR of 4.1% during the forecast period 2020-2025. The Anti-Hypertensive Drugs Market growth rate is attributed to increase in the number of patients suffering from hypertension, lifestyle changes such as dietary habits, increased penetration of generic drug versions and increased prevalence of chronic diseases. Reputable physicians are recommending antihypertensive drugs to treat hypertension or elevated blood pressure. One of the leading causes of heart failure, stroke, peripheral vascular disease, chronic kidney disease and others is long-term high blood pressure. There are many classes of antihypertensive drugs, which have the ability to lower blood pressure by different means, and thus, prevent the complications associated with high blood pressure, including stroke and myocardial infarction. Therefore, increase in prevalence of hypertension is anticipated to increase the Anti-Hypertensive Drugs therapeutics market share. Hypertension is characterized as a long-term medical condition marked by excessive blood pressure in the arteries, which is elevated persistently. Antihypertensive is used to treat people with elevated blood pressure-also known as hypertension. Hypertension is a serious condition with significant complications including heart attack, heart failure and dementia. Hypertension therefore demands early diagnosis and treatment. Some of the medicinal products used to treat hypertension include diuretics, ACE inhibitors, and vasodilators. From unavailability of promising treatment options with fewer side effects and complications associated with uncontrolled high blood pressure are compelling governments and private organizations to increase their R&D investments and motivating pharmaceutical companies to develop novel therapeutics to avoid incidences including kidney diseases, narrowed blood vessels in the eyes, and metabolic syndromes that can demonstrate better safety and efficacy than the available medications is anticipated to propel the Anti-Hypertensive Drugs Market during the forecast period 2020-2025. For instance, The US Food and Drug Administration (FDA) issued guidance on developing fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two-drug combinations of previously approved products. US FDA expects to see a reduction in adverse effects for combinations that include doses below each drugs’ maximum dose compared to single drug regimens at their maximum dose. Key Takeaways North America dominated the Anti-Hypertensive Drugs Market with a share of 34% in the year 2019. The factors such as increase in healthcare spending worldwide and increase in hypertension prevalence are amongst the major factor projected to impel growth of Anti-Hypertensive Drugs Market. Raising awareness of hypertension-related complications, increase in geriatric population and sedentary lifestyle are the key factors owing to the growth in the segment during forecast period 2020-2025. By Therapeutics Type - Segment Analysis On the basis of therapeutics type, diuretics segment held the major share of the market in terms of revenue and is anticipated to grow with a CAGR of 3.8%. The reason is attributed to the fact that in most patients thiazide diuretics are the cornerstone of hypertension treatment. Hydrochlorothiazide is the diuretic with thiazide most commonly used, resulted in the hike in demand for Anti-Hypertensive Drugs’. In addition, the U.S. Joint National Committee on the prevention, detection, evaluation and treatment of high blood pressure recommends thiazide-type diuretics as one of the preferred hypertension drug treatments and these continuous advancements in this field is anticipated to augment the diuretics segment. Apart from this, calcium channel blockers are poised to set the fastest growing segment in the forecast period 2020-2025. This is increasing the global demand owing to lesser side effects of these medicinal products compared with other antihypertensive drugs. In addition, the benefits offered such as positive effects on overall health and reductions in the progression of kidney diseases. By Geography - Segment Analysis North America dominated the Anti-Hypertensive Drugs Market with a share of 34% in 2019. The application of Anti-Hypertensive Drugs has grown rapidly over the last few years owing to easy use of antihypertensive medicines. In addition, the rise in hypertension incidence and the rise in geriatric population contribute significantly to market growth in this region. As per report published by the AHA (American heart association), 74.9% of hypertension patients are currently undergoing treatment, and only 52.2% of patients have it under control. AHA projection shows that by 2030, about 41.4% of adults in the United States are poised to have hypertension. Furthermore, some of the key market drivers on the North American anti-hypertension market are demanding for prompt and accurate diagnosis and treatment of hypertension, identification of people predisposed to the disease, presence of technically advanced healthcare infrastructure, and management of the disease prognosis. These factors, as well as the growing innovations in various anti-hypertensive drugs techniques, are anticipated to propel the Anti-Hypertensive Drugs Market during the forecast period 2020-2025. Asia-Pacific, however, is projected to record the highest growth during the forecast period 2020-2025, owing to a surge in awareness of antihypertensive drug use. In addition, the ever-evolving life science industry is driving market growth in developing economies such as India, China and Malaysia. Drivers – Anti-Hypertensive Drugs Market Rising awareness of the early detection of the disease With increasing prevalence of the disease, there has been an increase in awareness campaigns by non-profit and governmental organizations that have enabled improved diagnosis of hypertension. For instance, the Pulmonary Hypertension Association (PHA) offers education programs and has a strong support network which offers patients with right treatment information. Furthermore, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products and reducing the side effects of the procedures, providing a lucrative support to the Anti-Hypertensive Drugs market globally. Challenges – Anti-Hypertensive Drugs Market Lack of awareness and low drug adherence The major challenge for the market is the low awareness among the population of antihypertensive drugs. First, most people in developing countries are neglecting their health checks and are unaware of the hypertension condition in them until they detect extreme symptoms. Second, people diagnosed with hypertension do not adhere to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thus posing a huge challenge to the market for anti-hypertensive drugs. For instance, in 2016, BMC Research notes published a research survey (from a developing country) stating that only 17 percent of the total 112 hypertensive stroke subjects adhered to antihypertensive drugs. Anti-Hypertensive Drugs Industry Outlook Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Anti-Hypertensive Drugs Market. In 2019, Anti-Hypertensive Drugs Market share is fragmented by the top ten players present in the market. Anti-Hypertensive Drugs Market top 10 companies are AstraZeneca PLC, Boehringer Ingelheim, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd, Lupin Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited, Sanofi SA and others. Acquisitions/Product Launches In May 2017, Mankind Pharma, a global pharma company that manufactures and markets a broad range of healthcare products launches anti-hypertensive drug, Zolahart (Azilsartan), a new generation anti-hypertensive drug, offers potent and persistent 24 hours’ blood pressure control. It is proven to be safe for hypertensive patients with comorbid conditions like diabetes or chronic kidney disease (CKD). In April 2015, The US arm of the drug maker, Lupin Pharmaceuticals Inc., launched Amlodipine and Valsartan tablets in various strengths in the US market, for the treatment of hypertension and to lower blood pressure after getting final approval from the United States Food and Drug Administration (USFDA);